Fibronostics Expands U.S. Operations with Stone Clinical Laboratories Acquisition

Fibronostics, a leader in non-invasive diagnostics for metabolic and liver diseases, has completed its acquisition of Stone Clinical Laboratories, LLC. This strategic move, announced on October 27, 2025, aims to enhance Fibronostics’ laboratory capabilities in the United States and accelerate the development of innovative diagnostics for metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD).

The acquisition arrives during a transformative period for the industry, marked by significant developments such as the FDA approvals of Madrigal Pharmaceuticals’ RezdiffraTM and Novo Nordisk’s Wegovy®. Furthermore, Roche’s acquisition of 89Bio underscores the growing investments in MASH and MASLD therapeutics, as well as the increasing demand for diagnostics that can identify patients more effectively and monitor their treatment outcomes.

Strengthening Infrastructure and Expertise

“This acquisition expands our U.S. laboratory infrastructure and operational expertise,” stated Brock Smith, Chief Executive Officer of Fibronostics. He emphasized that the integration of Stone Clinical Laboratories will significantly bolster the company’s capacity to drive innovation in non-invasive diagnostics. The collaboration aims to enhance partnerships with pharmaceutical and healthcare stakeholders focused on addressing the global challenges posed by MASH and MASLD.

Stone Clinical Laboratories contributes extensive technical expertise and advanced testing capabilities that align with Fibronostics’ proprietary digital health platforms, including LIVERFASt®. Together, both organizations plan to advance biomarker development, research and development programs, and clinical validation studies that support therapeutic innovation and patient management.

Leading the Charge in Liver Health

“The therapeutic breakthroughs in MASH and MASLD are reshaping liver care,” added Smith. He noted that as treatment options expand, the need for precise and accessible diagnostics becomes increasingly critical. This acquisition positions Fibronostics to take a leading role in providing scalable solutions that effectively link diagnostics and therapeutics.

The deal signifies a pivotal step in Fibronostics’ growth strategy. With the combined resources and expertise of both companies, they are well-equipped to collaborate with biopharma innovators, healthcare systems, and payers. This collaboration aims to accelerate early detection and improve health outcomes for patients around the globe.

Fibronostics is recognized as a global health technology company specializing in non-invasive diagnostic solutions for chronic diseases, particularly liver and metabolic disorders. Its flagship platform, LIVERFASt®, empowers clinicians to evaluate liver health quickly and accurately. The company partners with pharmaceutical firms, diagnostic laboratories, and healthcare systems to advance next-generation liver diagnostics and enhance patient outcomes worldwide.

For further information, please contact:
Brock Smith, CEO
Fibronostics US Inc.
Phone: +1-888-552-1603
Email: [email protected]